Brief Summary
The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers:
* relapsed or refractory (R/R) lymphoma
* multiple myeloma
* newly diagnosed acute myeloid leukemia (AML).
This trial will be conducted in the outpatient setting in 2 parts, phase 1a and phase 1b. You may only participate in one part of the study.
During phase 1a of this study, we will explore how much maplirpacept (PF-07901801), when used by itself, can be safely used.
If you have lymphoma, the study medicine maplirpacept (PF-07901801) will be given by infusion through a vein once a week or once every 2 weeks or every 3 weeks as determined by your doctor. Following your first dose, you will be expected to come back twice more the first week. From week 2, you will have weekly visits for blood tests, questions about your medications, any side effects, or illnesses you may have experienced and your cancer response. After you have completed 21 days (for every week dosing) or 42 days (for every 2- or 3-weeks dosing), your doctor will discuss whether you should stop study treatment or continue.
If you continue, you will be expected to come back weekly for blood tests, vital signs, a brief physical exam, asked about any side effects or illnesses you may have experienced and medications you may be taking. The dosing schedule you are assigned to will continue until your disease has worsened, significant side effects occur or other reasons that lead you and your doctor to decide treatment may be stopped.
To be eligible for the first part of the study you must be 18 years or older, your disease has worsened after receiving other medicines approved for blood cancer, no other treatment options exist for you, a sample of your tissue for exploratory research which can be taken from tissue already obtained or if necessary, a new sample of your tissue will be taken so your disease may be seen and measured on routine tests/scans. If you have had radiation therapy or received any anticancer medication within 14 days before the planned start of study treatment your doctor will let you know if you are eligible to participate in the study. If you have had major surgery within 30 days before the planned start of study treatment you may not be eligible to participate.
The phase 1a part of the study may last up to 51/2 years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer responds to the study drug. Therefore, you may remain in the study as long as you and your study doctor think you may benefit. However, you are free to stop taking part in this study at any time and for any reason.
During phase 1b part of this study, we will explore how much maplirpacept (PF-07901801), when used with other anticancer medicine(s), can be safe and reduce cancer growth. In the phase 1b part of this study, you will receive maplirpacept (PF-07901801) and other anticancer medicine(s). Which medicine combination you will receive depends on the types of cancer under treatment. Your treatment experiences will be examined to determine if maplirpacept (PF-07901801) when given with other anticancer medicine(s), is safe and can reduce cancer growth.
To be eligible for the second part of the study you may have newly diagnosed Acute Myelocytic Leukemia with or without a genetic mutation or you have Multiple Myeloma or Diffuse Large B Cell Lymphoma, and your disease has worsened.
The Phase 1b part of this study may last as long as you and your study doctor think you may benefit which could be up to approximately 31/2 years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer responds to the study drug. Therefore, you may remain in the study as long as you and your study doctor think you may benefit. However, you are free to stop taking part in this study at any time and for any reason.
* relapsed or refractory (R/R) lymphoma
* multiple myeloma
* newly diagnosed acute myeloid leukemia (AML).
This trial will be conducted in the outpatient setting in 2 parts, phase 1a and phase 1b. You may only participate in one part of the study.
During phase 1a of this study, we will explore how much maplirpacept (PF-07901801), when used by itself, can be safely used.
If you have lymphoma, the study medicine maplirpacept (PF-07901801) will be given by infusion through a vein once a week or once every 2 weeks or every 3 weeks as determined by your doctor. Following your first dose, you will be expected to come back twice more the first week. From week 2, you will have weekly visits for blood tests, questions about your medications, any side effects, or illnesses you may have experienced and your cancer response. After you have completed 21 days (for every week dosing) or 42 days (for every 2- or 3-weeks dosing), your doctor will discuss whether you should stop study treatment or continue.
If you continue, you will be expected to come back weekly for blood tests, vital signs, a brief physical exam, asked about any side effects or illnesses you may have experienced and medications you may be taking. The dosing schedule you are assigned to will continue until your disease has worsened, significant side effects occur or other reasons that lead you and your doctor to decide treatment may be stopped.
To be eligible for the first part of the study you must be 18 years or older, your disease has worsened after receiving other medicines approved for blood cancer, no other treatment options exist for you, a sample of your tissue for exploratory research which can be taken from tissue already obtained or if necessary, a new sample of your tissue will be taken so your disease may be seen and measured on routine tests/scans. If you have had radiation therapy or received any anticancer medication within 14 days before the planned start of study treatment your doctor will let you know if you are eligible to participate in the study. If you have had major surgery within 30 days before the planned start of study treatment you may not be eligible to participate.
The phase 1a part of the study may last up to 51/2 years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer responds to the study drug. Therefore, you may remain in the study as long as you and your study doctor think you may benefit. However, you are free to stop taking part in this study at any time and for any reason.
During phase 1b part of this study, we will explore how much maplirpacept (PF-07901801), when used with other anticancer medicine(s), can be safe and reduce cancer growth. In the phase 1b part of this study, you will receive maplirpacept (PF-07901801) and other anticancer medicine(s). Which medicine combination you will receive depends on the types of cancer under treatment. Your treatment experiences will be examined to determine if maplirpacept (PF-07901801) when given with other anticancer medicine(s), is safe and can reduce cancer growth.
To be eligible for the second part of the study you may have newly diagnosed Acute Myelocytic Leukemia with or without a genetic mutation or you have Multiple Myeloma or Diffuse Large B Cell Lymphoma, and your disease has worsened.
The Phase 1b part of this study may last as long as you and your study doctor think you may benefit which could be up to approximately 31/2 years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer responds to the study drug. Therefore, you may remain in the study as long as you and your study doctor think you may benefit. However, you are free to stop taking part in this study at any time and for any reason.
Brief Title
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Detailed Description
This is a trial of maplirpacept (PF-07901801) in subjects with relapsed or refractory lymphoma or multiple myeloma (MM) and subjects with newly diagnosed acute myeloid leukemia (AML).
This trial will be conducted in 2 phases: Phase 1a (Dose-Escalation Phase for Single-Agent maplirpacept (PF-07901801) and Phase 1b maplirpacept (PF-07901801) Combinations and Single-Agent.
In the Dose-Escalation Phase for Single-Agent maplirpacept (PF-07901801), subjects with relapsed or refractory lymphoma will be enrolled in sequential dose cohorts.
In the Combination and Single-Agent Treatment part, subjects will be included in 1 of 14 cohorts: (Cohort A1 and A2) subjects with newly diagnosed TP53-mutated AML will be treated with maplirpacept (PF-07901801) + azacitidine; (Cohort B1 and B2) elderly subjects or subjects unfit for intensive induction chemotherapies with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) + azacitidine and venetoclax; (Cohort C1, C2, and C3) subjects with relapsed or refractory MM will be treated with maplirpacept (PF-07901801) + carfilzomib and dexamethasone;(Cohort D1 and D2) subjects in relapsed or refractory CD20+ diffuse large B-cell lymphoma will be treated with maplirpacept (PF-07901801) + an anti-CD20 targeting agent; (Cohort E1 and E2) subjects with relapsed refractory MM will be treated with single-agent maplirpacept (PF-07901801); and (Cohorts F1, F2 and F3) with relapsing or refractory MM will be treated with increasing doses of maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone.
This trial will be conducted in 2 phases: Phase 1a (Dose-Escalation Phase for Single-Agent maplirpacept (PF-07901801) and Phase 1b maplirpacept (PF-07901801) Combinations and Single-Agent.
In the Dose-Escalation Phase for Single-Agent maplirpacept (PF-07901801), subjects with relapsed or refractory lymphoma will be enrolled in sequential dose cohorts.
In the Combination and Single-Agent Treatment part, subjects will be included in 1 of 14 cohorts: (Cohort A1 and A2) subjects with newly diagnosed TP53-mutated AML will be treated with maplirpacept (PF-07901801) + azacitidine; (Cohort B1 and B2) elderly subjects or subjects unfit for intensive induction chemotherapies with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) + azacitidine and venetoclax; (Cohort C1, C2, and C3) subjects with relapsed or refractory MM will be treated with maplirpacept (PF-07901801) + carfilzomib and dexamethasone;(Cohort D1 and D2) subjects in relapsed or refractory CD20+ diffuse large B-cell lymphoma will be treated with maplirpacept (PF-07901801) + an anti-CD20 targeting agent; (Cohort E1 and E2) subjects with relapsed refractory MM will be treated with single-agent maplirpacept (PF-07901801); and (Cohorts F1, F2 and F3) with relapsing or refractory MM will be treated with increasing doses of maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone.
Categories
Completion Date
Completion Date Type
Actual
Conditions
Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
1. Available fresh or archived tumor tissue.
2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
3. Adequate coagulation function.
4. Adequate hepatic function.
5. Adequate hematologic status.
6. Adequate renal function.
7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was pre-existing).
Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory, transfusion- independent lymphoma (Hodgkin or non-Hodgkin) per the 2014 Lugano classification.
Key Inclusion Criteria (Phase 1b Cohort A1 and A2): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).
Key Inclusion Criteria (Phase 1b Cohort B1 and B2): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.
Key Inclusion Criteria (Phase 1b Cohorts C1, C2, C3 and E1, E2, F1, F2, F3): Histologically documented relapsed/refractory Multiple Myeloma (MM).
Key Inclusion Criteria (Phase 1b Cohort D1 and D2): Pathologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
1. Known, current central nervous system disease involvement.
2. Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment (within 4 weeks for antibody-based therapies and within 8 weeks for cell-based therapies).
3. Subjects who have undergone radiation therapy within 14 days of study treatment administration.
4. Hematopoietic stem cell transplant within 90 days before the planned start of study treatment or subjects with active graft-vs-host disease, with the exception of Grade 1 skin involvement.
5. Major surgery within 30 days before planned start of study treatment.
1. Available fresh or archived tumor tissue.
2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
3. Adequate coagulation function.
4. Adequate hepatic function.
5. Adequate hematologic status.
6. Adequate renal function.
7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was pre-existing).
Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory, transfusion- independent lymphoma (Hodgkin or non-Hodgkin) per the 2014 Lugano classification.
Key Inclusion Criteria (Phase 1b Cohort A1 and A2): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).
Key Inclusion Criteria (Phase 1b Cohort B1 and B2): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.
Key Inclusion Criteria (Phase 1b Cohorts C1, C2, C3 and E1, E2, F1, F2, F3): Histologically documented relapsed/refractory Multiple Myeloma (MM).
Key Inclusion Criteria (Phase 1b Cohort D1 and D2): Pathologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
1. Known, current central nervous system disease involvement.
2. Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment (within 4 weeks for antibody-based therapies and within 8 weeks for cell-based therapies).
3. Subjects who have undergone radiation therapy within 14 days of study treatment administration.
4. Hematopoietic stem cell transplant within 90 days before the planned start of study treatment or subjects with active graft-vs-host disease, with the exception of Grade 1 skin involvement.
5. Major surgery within 30 days before planned start of study treatment.
Inclusion Criteria
Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
1. Available fresh or archived tumor tissue.
2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
3. Adequate coagulation function.
4. Adequate hepatic function.
5. Adequate hematologic status.
6. Adequate renal function.
7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was pre-existing).
Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory, transfusion- independent lymphoma (Hodgkin or non-Hodgkin) per the 2014 Lugano classification.
Key Inclusion Criteria (Phase 1b Cohort A1 and A2): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).
Key Inclusion Criteria (Phase 1b Cohort B1 and B2): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.
Key Inclusion Criteria (Phase 1b Cohorts C1, C2, C3 and E1, E2, F1, F2, F3): Histologically documented relapsed/refractory Multiple Myeloma (MM).
Key Inclusion Criteria (Phase 1b Cohort D1 and D2): Pathologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
1. Available fresh or archived tumor tissue.
2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
3. Adequate coagulation function.
4. Adequate hepatic function.
5. Adequate hematologic status.
6. Adequate renal function.
7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was pre-existing).
Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory, transfusion- independent lymphoma (Hodgkin or non-Hodgkin) per the 2014 Lugano classification.
Key Inclusion Criteria (Phase 1b Cohort A1 and A2): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).
Key Inclusion Criteria (Phase 1b Cohort B1 and B2): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.
Key Inclusion Criteria (Phase 1b Cohorts C1, C2, C3 and E1, E2, F1, F2, F3): Histologically documented relapsed/refractory Multiple Myeloma (MM).
Key Inclusion Criteria (Phase 1b Cohort D1 and D2): Pathologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Gender
All
Gender Based
false
Keywords
Neoplasms
Lymphoma
Myeloma
Leukemia
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT03530683
Org Class
Industry
Org Full Name
Pfizer
Org Study Id
TTI-622-01
Overall Status
Terminated
Phases
Phase 1
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Primary Outcomes
Outcome Description
To characterize the safety profile (incidence of AEs)
Outcome Measure
Phase 1a: Number of adverse events (AE) by severity
Outcome Time Frame
Through study completion, up to 18 months
Outcome Description
To characterize the safety profile (incidence of AEs) and
Outcome Measure
Phase 1a: Number of AEs by Frequency
Outcome Time Frame
Through study completion, up to 18 months
Outcome Description
To characterize the dose limiting toxicities (DLTs) of TTI-622.
Outcome Measure
Phase 1a: Number of participants with Dose-Limiting Toxicities (DLT)
Outcome Time Frame
Up to 21-42 days
Outcome Description
To characterize the safety profile (incidence of AEs) of TTI-622 given in combinations or as a single agent.
Outcome Measure
Phase 1b: Number of adverse events (AE) by severity
Outcome Time Frame
Through study completion, up to 30 months
Outcome Description
To characterize the safety profile (incidence of AEs) of TTI-622 given in combination or as a single agent.
Outcome Measure
Phase 1b: Number of adverse events (AE) by frequency
Outcome Time Frame
Through study completion, up to 30 months
Outcome Description
To evaluate response rate of each combination treatment in the (7) combination cohorts (A1,A2, B1, B2, C1, C2, C3, D1, D2, F1, F2, F3) and for single agent treatment (Cohort E1 and E2). For AML, response = CR. For MM, response = CR+sCR+VGBR+PR. For DLBCL, OR=CR+PR
Outcome Measure
Phase 1b: Number of participants with disease response
Outcome Time Frame
Through study completion, up to 30 months
Outcome Description
To characterize the highest dose level for which no more than 1 participant in a dose cohort experienced DLTs.
Outcome Measure
Phase 1a: Maximum Tolerated Dose (MTD)
Outcome Time Frame
Baseline (the start of each sequentially increased treatment dose), up to the 3rd evaluable patient completes DLT observation period of 21 or 42 days.
Outcome Description
To characterize the recommended dose of TTI-622 in combination with selected anticancer treatments in 5 patient populations:
* TTI-622 plus azacitidine in newly diagnosed TP53-mutated AML
* TTI-622 plus azacitidine and venetoclax in elderly (\>/= 75 years old) or unfit, newly diagnosed TP53-wildtype AML
* TTI-622 plus Carfilzomib and dexamethasone in Carfilzomib-refractory, Relapsed/Refractory (R/R) multiple myeloma (MM) after 3 or more prior lines of therapy
* TTI-622 plus an anti-CD20 targeting agent (such as ruxience or rituxan) in R/R CD20+ DLBCL after 1 or more prior lines of therapy
* TTI-622 plus isatuximab, carfilzomib and dexamethasone in R/R MM after 1-3 prior lines of therapy
* TTI-622 plus azacitidine in newly diagnosed TP53-mutated AML
* TTI-622 plus azacitidine and venetoclax in elderly (\>/= 75 years old) or unfit, newly diagnosed TP53-wildtype AML
* TTI-622 plus Carfilzomib and dexamethasone in Carfilzomib-refractory, Relapsed/Refractory (R/R) multiple myeloma (MM) after 3 or more prior lines of therapy
* TTI-622 plus an anti-CD20 targeting agent (such as ruxience or rituxan) in R/R CD20+ DLBCL after 1 or more prior lines of therapy
* TTI-622 plus isatuximab, carfilzomib and dexamethasone in R/R MM after 1-3 prior lines of therapy
Outcome Measure
Phase 1b: Recommended dose of TTI-622 in combination with selected anticancer treatments
Outcome Time Frame
Through study completion, up to 30 months
Outcome Description
To characterize the recommended dose of TTI-622 as a single agent in patients with R/R MM after 3 or more prior lines of therapy.
Outcome Measure
Phase 1b: Recommended dose of TTI-622 as a single agent
Outcome Time Frame
Through study completion, up to 30 months
Outcome Description
To evaluate preliminary efficacy of each combination treatment in the selected patient populations and for single-agent treatment in R/R MM
Outcome Measure
Number of participants with response assessments that show preliminary efficacy
Outcome Time Frame
Through study completion, up to 30 months
Secondary Ids
Secondary Id
C4971001
Secondary Outcomes
Outcome Description
To characterize AUC0-t of TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: TTI-622 PK parameter AUC0-t
Outcome Description
To characterize Cmax of TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: TTI-622 PK parameter Cmax
Outcome Description
To characterize the immunogenicity of TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Incidence of anti-drug antibodies (ADA)
Outcome Description
To determine the disease response.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Number of participants with overall response rate (ORR) for participants treated with TTI-622.
Outcome Description
To determine the disease control rate (DCR) for participants treated with TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Number of participants with disease control rate (DCR)
Outcome Description
To determine the time to response (TTR) for participants treated with TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Time to response (TTR)
Outcome Description
To determine the duration of response (DR) for participants treated with TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Duration of Response (DR)
Outcome Description
To determine the progression free survival (PFS) time for participants treated with TTI-622.
Outcome Time Frame
Through study completion, up to 18 months
Outcome Measure
Phase 1a: Progression free survival (PFS)
Outcome Description
To characterize Cmax of TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: TTI-622 PK parameter Cmax when combined with selected anticancer treatments or as a single agent
Outcome Description
To characterize the immunogenicity of TTI-622 when combined with selected anticancer treatments or as a single agent
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: incidence of anti-drug antibodies (ADA) Immunogenicity of TTI-622 when combined with selected anticancer treatments or as a single agent
Outcome Description
To determine the disease control rate (DCR) for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Number of participants with disease control rate (DCR)
Outcome Description
To determine the time to response (TTR) for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Time to response (TTR)
Outcome Description
To determine event-free survival (EFS; for Cohorts A and B) time for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Event-free survival (EFS)
Outcome Description
To determine the duration of response (DOR) for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Duration of response (DR)
Outcome Description
To determine the progression-free survival (PFS) time for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Progression-free survival (PFS)
Outcome Description
To determine minimal residual disease (MRD; for Cohorts A, B, C , E and F) for participants treated with TTI-622 when combined with selected anticancer treatments or as a single agent.
Outcome Time Frame
Through study completion, up to 30 months
Outcome Measure
Phase 1b: Number of Participants With Minimal Residual Disease Burden (MRD) Positive, Negative and Not Evaluable (NE) Status
See Also Links
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Actual
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Ioannis Mantzaris
Investigator Email
IMANTZAR@montefiore.org
Categories Mesh Debug
Blood & Bone Marrow Cancers --- MULTIPLE MYELOMA
Blood & Bone Marrow Cancers --- LEUKEMIA, MYELOID, ACUTE
Cancer --- NEOPLASMS
Blood & Bone Marrow Cancers --- NEOPLASMS, PLASMA CELL
Cancer --- LEUKEMIA
Blood & Bone Marrow Cancers --- LEUKEMIA
Blood & Bone Marrow Cancers --- LYMPHOPROLIFERATIVE DISORDERS
Blood & Bone Marrow Cancers --- LYMPHATIC DISEASES
Blood & Bone Marrow Cancers --- IMMUNOPROLIFERATIVE DISORDERS
Infectious Disease --- IMMUNE SYSTEM DISEASES
Lung --- IMMUNE SYSTEM DISEASES
Blood & Bone Marrow Cancers --- HEMOSTATIC DISORDERS
Blood & Bone Marrow Cancers --- VASCULAR DISEASES
Heart/Cardiovascular --- VASCULAR DISEASES
Blood Disorders --- CARDIOVASCULAR DISEASES
Blood & Bone Marrow Cancers --- CARDIOVASCULAR DISEASES
Heart/Cardiovascular --- CARDIOVASCULAR DISEASES
Blood & Bone Marrow Cancers --- PARAPROTEINEMIAS
Blood & Bone Marrow Cancers --- BLOOD PROTEIN DISORDERS
Blood Disorders --- HEMATOLOGIC DISEASES
Blood & Bone Marrow Cancers --- HEMATOLOGIC DISEASES
Blood & Bone Marrow Cancers --- HEMORRHAGIC DISORDERS
Blood & Bone Marrow Cancers --- LEUKEMIA, MYELOID
MeSH Terms
LYMPHOMA
MULTIPLE MYELOMA
LEUKEMIA, MYELOID, ACUTE
LYMPHOMA, LARGE B-CELL, DIFFUSE
NEOPLASMS
NEOPLASMS, PLASMA CELL
LEUKEMIA
NEOPLASMS BY HISTOLOGIC TYPE
LYMPHOPROLIFERATIVE DISORDERS
LYMPHATIC DISEASES
HEMIC AND LYMPHATIC DISEASES
IMMUNOPROLIFERATIVE DISORDERS
IMMUNE SYSTEM DISEASES
HEMOSTATIC DISORDERS
VASCULAR DISEASES
CARDIOVASCULAR DISEASES
PARAPROTEINEMIAS
BLOOD PROTEIN DISORDERS
HEMATOLOGIC DISEASES
HEMORRHAGIC DISORDERS
LEUKEMIA, MYELOID
LYMPHOMA, B-CELL
LYMPHOMA, NON-HODGKIN
AZACITIDINE
VENETOCLAX
CARFILZOMIB
DEXAMETHASONE
RITUXIMAB
ISATUXIMAB
AZA COMPOUNDS
ORGANIC CHEMICALS
CYTIDINE
PYRIMIDINE NUCLEOSIDES
PYRIMIDINES
HETEROCYCLIC COMPOUNDS, 1-RING
HETEROCYCLIC COMPOUNDS
NUCLEOSIDES
NUCLEIC ACIDS, NUCLEOTIDES, AND NUCLEOSIDES
RIBONUCLEOSIDES
PREGNADIENETRIOLS
PREGNADIENES
PREGNANES
STEROIDS
FUSED-RING COMPOUNDS
POLYCYCLIC COMPOUNDS
STEROIDS, FLUORINATED
ANTIBODIES, MONOCLONAL, MURINE-DERIVED
ANTIBODIES, MONOCLONAL
ANTIBODIES
IMMUNOGLOBULINS
IMMUNOPROTEINS
BLOOD PROTEINS
PROTEINS
AMINO ACIDS, PEPTIDES, AND PROTEINS
SERUM GLOBULINS
GLOBULINS